[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334283-105":59,"doc-detail-334283-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","precision-treatment-of-metachronous-multiple-primary-malignancies-based-on-constructing-patient-tumor-derived-organoids","Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived Organoids","","Multiple primary malignant neoplasms (MPMNs) are defined as two or more primary tumors while excluding diffuse, recurrent, or metastatic disease, yet clinical examples with three urinary tract cancers remain exceptionally rare. A case with four primary malignancies—three urinary tract cancers and lung cancer—developed over 13 years, and pathology after different surgeries confirmed they were all primary tumors. Patient-derived organoids (PDOs) established from tumor specimens reproduced parental histology via H&E staining and reflected pathological marker expression by immunohistochemistry, supporting PDOs as “avatars” for drug-sensitivity prediction. A personalized treatment strategy based on organoid histopathology was developed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/precision-treatment-of-metachronous-multiple-primary-malignancies-based-on-constructing-patient-tumor-derived-organoids/334283/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/precision-treatment-of-metachronous-multiple-primary-malignancies-based-on-constructing-patient-tumor-derived-organoids/334283.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines multiple primary malignant neoplasms (MPMNs) in the article?","Question",{"text":112,"@type":113},"MPMNs are defined by the presence of two or more malignant primary neoplasms while excluding diffuse, recurrent, or metastatic tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patient-derived organoids (PDOs) used in the reported case?",{"text":117,"@type":113},"PDOs were generated from collected tumor specimens, and H&E staining showed histopathological consistency with the parental tumors. Immunohistochemistry further indicated PDOs can reflect expression of pathological markers.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed value of PDOs for treatment planning?",{"text":121,"@type":113},"PDOs are described as patient “avatars” that may predict sensitivity to different drugs, enabling a personalized treatment strategy based on organoid histopathological characteristics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334283,1790193864,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nPrecision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived Organoids  \nYicheng Wang 1,2,3,†, Haotian Chen 1,3,†, Zhijin Zhang 1,3, Yanyan He 1,4, Ji Liu 1,3, Baoshuang Zhao 5, Qinwan Wang 6, Jiangmei Xu 1,3, Shiyu Mao 1,3, Wentao Zhang 1,3, *, Xudong Yao 1,3 and Wei Li 1,3, *  \nCitation: Wang, Y.; Chen, H.; Zhang, Z.; He, Y.; Liu, J.; Zhao, B.; Wang, Q.; Xu, J.; Mao, S.; Zhang, W.; et al. Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient TumorDerived Organoids. Biomedicines 2024, 12, 2708. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomedicines12122708  \nAcademic Editors: Georgia Levidou, Pedro A. José and Christos K. Kontos  \nReceived: 26 July 2024  \nRevised: 25 August 2024  \nAccepted: 30 August 2024  \nPublished: 27 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China; [2050700@tongji.edu.cn](2050700@tongji.edu.cn) (Y.W.); [chenhaotian9710@163.com](chenhaotian9710@163.com) (H.C.); [2231200@tongji.edu.cn](2231200@tongji.edu.cn) (Z.Z.); [13661483022@163.com](13661483022@163.com) (Y.H.); [drliu7087797@163.com](drliu7087797@163.com) (J.L.); [aiyu5410@163.com](aiyu5410@163.com) (J.X.); [maoshiyu1144@sina.com](maoshiyu1144@sina.com) (S.M.); [yaoxudong1967@163.com](yaoxudong1967@163.com) (X.Y.)  \n2 School of Medicine, Tongji University, Shanghai 200092, China  \n3 Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai 200435, China  \n4 Department of Pathology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China  \n5 Department of Hepatobiliary Surgery, Yiwu Central Hospital, Yiwu 322000, China; [baidubuqin0302@sina.com](baidubuqin0302@sina.com)  \n6 Department of Central Laboratory, Clinical Medicine Scientific and Technical Innovation Park, Shanghai Tenth People’s Hospital, Shanghai 200435, China; [qinwan_yiyi2011@163.com](qinwan_yiyi2011@163.com)  \n* Correspondence: [zhangwentao98@163.com](zhangwentao98@163.com) (W.Z.); [weili06@tongji.edu.cn](weili06@tongji.edu.cn) (W.L.)† These authors contributed equally to this work.  \nAbstract: When a patient has two or more primary tumors, excluding the possibility of diffuse, recurrent, or metastatic, they can be defined as having multiple primary malignant neoplasms (MPMNs) . Moreover, cases of three primary urinary tract tumors are very rare. Here, we reported a patient of MPMNs with four primary tumors, including three urinary tract cancers (renal cancer, prostate cancer, and bladder cancer) and lung cancer. The four tumors appeared over 13 years, and pathological results confirmed that they were all primary tumors after different surgeries. In addition, we established patient-derived organoids (PDOs) by collecting tumor specimens. Hematoxylin-eosin (H&E) staining of PDOs showed that the organoids were histopathological consistent with parental tumor. Immunohistochemistry showed that PDOs can also reflect the expression of pathological markers in patients. At the same time, PDOs may also serve as “avatars” of patients to predict sensitivity to different drugs. In summary, we reported a case of MPMNs with four primary tumorsand established PDOs from its tumor specimens. A personalized treatment strategy was established based on the histopathological characteristics of the organoids.  \nKeywords: multiple primary malignant neoplasms (MPMNs); patient-derived organoids; precision medicine  \n1. Introduction  \nWith the advancement of diagnostic techniques, ","cbCaicePy8FBHqGX","https://ap.wps.com/l/cbCaicePy8FBHqGX","pdf",3282927,12,"English","# Introduction\n# Materials and Methods\n# Results\n# Discussion\n# Conclusions","[{\"question\":\"What defines multiple primary malignant neoplasms (MPMNs) in the article?\",\"answer\":\"MPMNs are defined by the presence of two or more malignant primary neoplasms while excluding diffuse, recurrent, or metastatic tumors.\"},{\"question\":\"How were patient-derived organoids (PDOs) used in the reported case?\",\"answer\":\"PDOs were generated from collected tumor specimens, and H\\u0026E staining showed histopathological consistency with the parental tumors. Immunohistochemistry further indicated PDOs can reflect expression of pathological markers.\"},{\"question\":\"What is the proposed value of PDOs for treatment planning?\",\"answer\":\"PDOs are described as patient “avatars” that may predict sensitivity to different drugs, enabling a personalized treatment strategy based on organoid histopathological characteristics.\"}]","Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived Organoids | PDF",1790006119]